Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors

BJU International

Volumn 97, Issue 2, 2006, Pages 404-409

  Helenius, Merja A ^a   Savinainen, Kimmo J ^a   Bova, G Steven ^b   Visakorpi, Tapio ^a,c  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TAMPERE   (Finland)

Author keywords

Gene amplification; PLAU; Prostate cancer; Urokinase

Indexed keywords

4 AMINOBENZAMIDINE; AMILORIDE; B 428; MATRIGEL; PLASMINOGEN ACTIVATOR INHIBITOR; UNCLASSIFIED DRUG; UROKINASE; PLASMA PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RECURRENCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME INHIBITION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; EVALUATION; GENETICS; METHODOLOGY; NEOPLASM; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE;

AMILORIDE; BLOOD PROTEINS; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; URINARY PLASMINOGEN ACTIVATOR;

EID: 33644872871     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05912.x     Document Type: Article

References (46)

1. Hsing AW Tsao L Devesa SS International trends and patterns of prostate cancer incidence and mortality Int J Cancer 2000 85 60 7
2. Kallioniemi OP Visakorpi T Genetic basis and clonal evolution of human prostate cancer Adv Cancer Res 1996 68 225 55
3. Dano K Romer J Nielsen BS et al. Cancer invasion and tissue remodelling - cooperation of protease systems and cell types APMIS 1999 107 120 7
4. Festuccia C Dolo V Guerra F et al. Plasminogen activation system modulates invasive capacity and proliferation in prostatic tumor cells Clin Exp Metastasis 1998 16 513 28
5. Andreasen PA Kjoller L Christensen L Duffy MJ The urokinase-type plasminogen activator system in cancer metastasis: a review Int J Cancer 1997 72 1 22
6. Blasi F Vassalli JD Dano K Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors J Cell Biol 1987 104 801 4
7. Dano K Behrendt N Brunner N Ellis V Ploug M Pyke C The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion Fibrinolysis 1994 8 189 203
8. Ellis V Behrendt N Dano K Plasminogen activation by receptor bound urokinase J Biol Chem 1991 266 752 8
9. Vines DJ Lee SW Dichek DA Ellis V Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase J Pept Sci 2000 6 432 9
10. Liotta L Goldfarb R Brundage R Siegel G Terranova V Garbisa S Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components on basement membrane Cancer Res 1981 41 4629 36
11. Mueller BM Different roles for plasminogen activators and metalloproteinases in melanoma metastasis Curr Top Microbiol Immunol 1996 213 65 80
12. Murphy G Atkinson S Ward R Gavrilovic J Reynolds JJ The role of plasminogen activators in the regulation of connective tissue metalloproteases Ann NY Acad Sci 1992 667 1 12
13. Naldini L Vugna E Bartelli A Follenzi A Galimi F Comoglio PM Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction J Biol Chem 1995 270 603 11
14. Nishimura K Matsumiya K Miura H et al. Effects of hepatocyte growth factor on urokinase-type plasminogen activator (uPA) and uPA receptor in DU145 prostate cancer cells Int J Androl 2003 26 175 9
15. Andreasen PA Georg B Lund LR Riccio A Stacey SN Plasminogen activator inhibitors: hormonally regulated serpins Mol Cell Endocrinol 1990 68 1 19
16. Gaylis FD Keer HN Wilson MJ Kwaan HC Sihna AA Kozlowski JM Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype J Urol 1989 142 193 8
17. Van Veldhuizen PJ Sadasivan R Cherian R Wyatt A Urokinase-type plasminogen activator expression in human prostate carcinomas Am J Med Sci 1996 312 8 11
18. Look MP Foeckens JA Clinical relevance of the urokinase plasminogen activator system in breast cancer APMIS 1999 107 150 9
19. Skriver L Larsson LI Kielberg V et al. Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carsinoma J Cell Biol 1984 99 752 7
20. Chu QD Hurd TC Harvey S et al. Overexpression of urinary plasminogen activator (uPA) protein and mRNA in thyroid carsinogenesis Diagn Mol Pathol 2004 13 241 6
21. Pyke C Kristensen P Ralfkieraer E et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas Am J Pathol 1991 138 1059 67
22. Hsu DW Efird JT Hedley-Whyte ET Prognostic role of urokinase-type plasminogen activator in human gliomas Am J Pathol 1995 147 114 23
23. Miyake H Hara I Yamanaka K Arakawa S Kamidono S Elevation of urokinase-type plasminogen activator and its receptor densities as new predictor of disease progression and prognosis in men with prostate cancer Int J Oncol 1999 14 535 41
24. Yang JL Seetoo DQ Wang Y et al. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factor of metastasis and cancer-specific survival and potential therapeutic targets Int J Cancer 2000 89 431 9
25. Hollas W Hoosein N Chung LW et al. Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines Thromb Haemost 1992 68 662 6
26. Helenius MA Saramäki OR Linja MJ Tammela TL Visakorpi T Amplification of urokinase gene in prostate cancer Cancer Res 2001 61 5340 4
27. Hyytinen E Visakorpi T Kallioniemi A Kallioniemi OP Isola JJ Improved technique for analysis of formalin-fixed paraffin-embedded tumors by fluorescence in situ hybridization Cytometry 1994 16 93 9
28. Saramäki O Willi N Bratt O et al. Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer Am J Pathol 2001 159 2089 94
29. Jankun J Keck RW Skrzypezak-Jankun E Swietcz R Inhibitors of urokinase reduces size of prostate cancer xenografts in severe combined immunodeficient mice Cancer Res 1997 57 559 63
30. Towle MJ Lee A Maduakor EC Schwartz CE Bridges AJ Littlefield BA Inhibition of urokinase by 4-substited benzo (b) thiophene-2-carboxamidine: an important new class of selective synthetic urokinase inhibitor Cancer Res 1993 53 2553 9
31. Alonso DF Tejera AM Farias EF Bal de Kier Joffe E Gomez DE Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428 Anticancer Res 1998 18 4499 504
32. Evans DM Sloan-Stakleff K Suppression of the invasive capacity of human breast cancer cells by inhibition of urokinase plasminogen activator via amiloride and B428 Am Surg 2000 66 460 4
33. Webber MM Waghray A Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid Clin Cancer Res 1995 1 755 61
34. Cher ML Biliran HR Bhagat S et al. Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis Proc Natl Acad Sci USA 2003 100 7847 52
35. McGowen R Biliran H Sager R Sheng S The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin Cancer Res 2000 60 4771 8
36. Ray P Bhatti R Gadarowski J Bell N Nasruddin S Inhibitory effect of amiloride on the urokinase plasminogen activators in prostate cancer Tumour Biol 1998 19 60 4
37. Jankun J Skrzypczak-Jankun E Binding site of amiloride to urokinase plasminogen activator depends on species Int J Mol Med 2001 8 365 71
38. Tang CM Presser F Morad M Amoloride selectively blocks the low threshold (T) calcium channel Science 1988 240 213 5
39. Kleyman TR Kragoe EJ Jr. Amiloride and its analogs as tools in the study of ion transport J Membr Biol 1988 105 1 21
40. Billstrom A Hartley-Asp B Lecander I Batra S Astedt B The urokinase inhibitor p-aminobenzamidine inhibits growth of a human prostate tumor in SCID mice Int J Cancer 1995 61 542 7
41. Holst-Hansen C Johannessen B Hoyer-Hansen G Romer J Ellis V Brunner N Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness Clin Exp Metastasis 1996 14 297 307
42. Xing RH Rabbani SA Regulation of urokinase production by androgens in human prostate cancer cells: effect of tumor growth and metastases in vivo Endocrinology 1999 140 4056 64
43. Vogel CL Cobleigh MA Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 2002 20 719 26
44. Sawyers C Targeted cancer therapy Nature 2004 432 294 7
45. Lynch TJ Bell DW Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 2004 350 2129 39
46. Paez JG Janne PA Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 2004 304 1497 500